Global Protein Degeneration Therapy Market Size, Share, Trends & Growth Analysis Report Segmented By Type (Bavdegalutamide (ARV-11), Vepdegestrant (ARV-471), Other Types), Application, End User And Regions (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), 2026-2034

Protein Degeneration Therapy Market Size Overview

The Protein Degeneration Therapy Market size was valued at USD 1.75 Billion in 2025 and is projected to grow from USD 1.90 Billion in 2026 to USD 3.70 Billion by 2034, at a CAGR of 8.67% during the forecast period.

The protein degeneration therapy market is poised for significant expansion, driven by its groundbreaking approach to drug discovery that targets and eliminates disease-causing proteins. A key driver is the increasing prevalence of intractable diseases, particularly various forms of cancer and neurodegenerative disorders, which often lack effective conventional treatments. This innovative therapeutic modality, primarily involving Proteolysis-Targeting Chimeras (PROTACs) and molecular glues, offers the potential to address previously "undruggable" targets. Opportunities within the market are vast, extending across a wide range of therapeutic areas, including oncology, neurology, and infectious diseases, by offering highly selective and catalytic degradation mechanisms. The robust research and development pipeline, coupled with strategic collaborations between pharmaceutical and biotechnology companies, further propels the market's growth, promising transformative solutions for numerous debilitating conditions.

Market Dynamics

Protein Degeneration Therapy Market Drivers

• Rising Prevalence of Chronic and Intractable Diseases: The escalating global burden of chronic and intractable diseases, particularly various forms of cancer and a growing number of neurodegenerative disorders, is a primary driver for the protein degeneration therapy market. Traditional therapies often face limitations in efficacy or encounter drug resistance, leaving significant unmet medical needs. For instance, the World Health Organization reported in February 2024 that over 35 million new cancer cases are projected for 2050, representing a 77% increase from the 20 million cases predicted in 2022. This alarming rise underscores the urgent demand for novel therapeutic modalities. Protein degeneration therapies, by offering a fundamentally different mechanism of action – the selective elimination of disease-causing proteins – present a promising avenue for treating diseases that have historically been challenging to address, thereby fueling intense research and development in this innovative field.
• Advancements in Understanding Protein Homeostasis and Degradation Pathways: Significant scientific breakthroughs in understanding the intricate mechanisms of cellular protein homeostasis and the ubiquitin-proteasome system (UPS) are critically driving the protein degeneration therapy market. Researchers now possess a deeper insight into how proteins are ubiquitinated and subsequently degraded by the proteasome, which is the cellular machinery responsible for recycling proteins. This enhanced molecular understanding enables the rational design of targeted protein degraders, such as PROTACs and molecular glues, that effectively hijack these natural cellular pathways. Continued funding from government research agencies like the National Institutes of Health in the United States, supporting basic research into protein biochemistry and cell biology, provides the foundational knowledge necessary to develop highly specific and potent protein degraders, accelerating the pace of therapeutic innovation.
• Potential to Target "Undruggable" Proteins: One of the most compelling drivers for the protein degeneration therapy market is its unique ability to target and degrade proteins that have historically been considered "undruggable" by conventional small molecule inhibitors. Traditional drugs typically require a binding pocket on the target protein to inhibit its function, but many disease-relevant proteins lack such accessible sites. Protein degraders, conversely, work by inducing proximity between a target protein and an E3 ubiquitin ligase, leading to the target's degradation, irrespective of an active site. This opens up vast new therapeutic avenues. According to a 2023 study published in Nature Reviews Drug Discovery, approximately 80% of the human proteome remains challenging to target with traditional drugs, highlighting the immense potential for protein degradation therapies to address a wide array of previously inaccessible disease drivers.
• Increasing Investment and Collaborative Research: The protein degeneration therapy market is experiencing a significant surge in investment from pharmaceutical and biotechnology companies, alongside a growing number of strategic collaborations. This robust financial backing and partnership activity accelerate the pace of drug discovery and development. For instance, data from industry analyses frequently show a marked rise in venture capital funding directed towards companies focused on targeted protein degradation platforms. These collaborations often involve licensing agreements, co-development deals, and joint research initiatives that pool resources, share expertise, and mitigate the inherent risks associated with early-stage drug development. This collaborative ecosystem, often supported by government grants for translational research, fosters a synergistic environment that propels the rapid advancement of protein degradation therapies from preclinical stages to clinical trials.

Protein Degeneration Therapy Market Opportunities

• Expansion into Neurodegenerative Diseases: The application of protein degeneration therapy in treating neurodegenerative diseases represents a vast and largely untapped market opportunity. Conditions such as Alzheimer's, Parkinson's, and Huntington's disease are characterized by the accumulation of misfolded or aggregated proteins in the brain, for which current treatments offer only symptomatic relief. Protein degraders offer a novel approach to directly remove these pathological proteins. A review article in Cell Reports (2023) indicates that over 20% of recent targeted protein degradation research initiatives are focused on neurodegenerative disorders, underscoring the significant research interest. The immense unmet medical need, coupled with a deeper understanding of proteinopathy in these conditions, positions protein degeneration therapies as a transformative solution, attracting substantial investment and fostering a rich pipeline of therapeutic candidates.
• Addressing Drug Resistance in Oncology: Protein degeneration therapy offers a critical opportunity to overcome drug resistance, a major challenge in oncology. Cancer cells often develop resistance to conventional therapies, such as kinase inhibitors, by acquiring mutations or upregulating alternative pathways. Protein degraders can circumvent some resistance mechanisms because they act catalytically and do not require tight binding to an active site for their effect. This allows them to effectively degrade target proteins even if they are mutated in ways that render traditional inhibitors ineffective. Clinical trials, as reported by national cancer institutes, are actively investigating protein degraders in resistant cancer settings. The potential to provide new treatment options for patients with refractory cancers represents a significant and compelling market opportunity, enhancing the efficacy and extending the benefits of targeted cancer therapies.
• New Therapeutic Avenues for Infectious Diseases: The application of protein degeneration therapy is emerging as a promising new therapeutic avenue for infectious diseases, offering a novel mechanism to combat viral and bacterial pathogens. Instead of inhibiting pathogen proteins, degraders can be designed to directly eliminate them, potentially circumventing resistance mechanisms that arise from traditional antiviral or antibacterial drugs. This approach can target viral replication enzymes, bacterial virulence factors, or even host proteins hijacked by pathogens. Research funded by public health organizations, such as the Centers for Disease Control and Prevention (CDC), increasingly explores host-targeted therapies. The growing threat of antimicrobial resistance and the need for new treatment modalities for emerging infectious diseases create a significant and urgent market opportunity for protein degeneration therapies to provide innovative solutions against resistant pathogens.
• Personalized Medicine and Biomarker-Driven Therapies: The protein degeneration therapy market presents a strong opportunity in the realm of personalized medicine and biomarker-driven therapies. The highly specific nature of these degraders allows for the development of treatments tailored to a patient's unique molecular profile, particularly in oncology where specific protein overexpression or mutations drive disease. By identifying specific biomarkers that indicate susceptibility to a particular degrader, clinicians can select patients most likely to respond, leading to more effective and safer treatments. The U.S. National Cancer Institute emphasizes biomarker-guided therapy development for improved patient outcomes. This precision medicine approach not only enhances therapeutic efficacy but also reduces adverse effects by targeting only the relevant proteins, creating a significant value proposition and market demand for highly personalized protein degradation therapies.

Protein Degeneration Therapy Market Restrain & Challenges

• Off-Target Effects and Selectivity Concerns: A significant restraint and challenge for protein degeneration therapy is the potential for off-target effects and ensuring high selectivity. While the promise of targeted degradation lies in its specificity, designing molecules that precisely recruit only the intended E3 ligase to the desired target protein, without affecting other crucial proteins, is complex. Unintended interactions or degradation of off-target proteins could lead to undesirable side effects and toxicity, complicating clinical development and patient safety. Research published in scientific journals on drug discovery consistently highlights the ongoing efforts required to minimize these off-target interactions. The stringent regulatory requirements from bodies like the U.S. Food and Drug Administration demand extensive preclinical and clinical data to demonstrate a favorable safety profile, adding considerable time and cost to drug development.
• Challenges in Oral Bioavailability and Drug Delivery: Many protein degradation therapy molecules, particularly larger PROTACs, face significant challenges related to their oral bioavailability and effective drug delivery to target tissues. Their relatively larger molecular weight and complex chemical structures can hinder their absorption across the gut wall and limit their ability to penetrate cell membranes or cross the blood-brain barrier. This often necessitates alternative administration routes, such as intravenous injections, which can be less convenient for patients and increase healthcare costs. Overcoming these pharmacokinetic and pharmacodynamic hurdles requires extensive formulation development and innovative drug delivery strategies. Research supported by national health organizations actively investigates new delivery platforms, but these complexities can slow down development timelines and limit the accessibility of these promising therapies.
• High Development Costs and Lengthy Clinical Trials: The protein degeneration therapy market is constrained by the inherently high costs and lengthy timelines associated with drug discovery, preclinical development, and clinical trials. Developing novel therapeutics, especially those with new mechanisms of action, requires substantial financial investment in complex biochemical assays, structural biology studies, and rigorous toxicology assessments. Clinical trials for these innovative therapies often involve multiple phases, spanning several years, with significant expenditure on patient recruitment, data collection, and regulatory submissions. For instance, industry analyses frequently highlight the multi-billion dollar cost of bringing a single new drug to market. This immense financial burden and extended development cycle can deter investment, particularly for smaller biotechnology firms, and delay the availability of new treatments to patients.
• Complex Regulatory Landscape and Manufacturing Hurdles: The novel nature of protein degeneration therapies presents a complex and evolving regulatory landscape, posing significant challenges for market entry and commercialization. Regulatory agencies globally are still establishing specific guidelines for these new modalities, which can lead to uncertainties in the approval pathway. Manufacturers must navigate intricate requirements for drug quality, safety, and efficacy, which may differ across jurisdictions. Furthermore, the specialized manufacturing processes for these complex molecules, often involving multi-step chemical synthesis and purification, can present significant scale-up challenges. Ensuring consistent product quality and adhering to Good Manufacturing Practices (GMP) for these intricate molecules adds to the complexity and cost of production, requiring substantial expertise and investment in specialized facilities.

Current Trends in the Protein Degeneration Therapy Market

• Advancements in PROTAC Design and Optimization: A significant trend in the protein degeneration therapy market is the continuous advancement in the design and optimization of PROteolysis-Targeting Chimeras (PROTACs). Researchers are developing more sophisticated PROTAC molecules with improved potency, selectivity, and pharmacokinetic properties. This involves exploring diverse E3 ubiquitin ligase recruiting ligands, optimizing linker chemistry, and fine-tuning the binding affinity to target proteins. These advancements aim to reduce off-target effects, improve oral bioavailability, and enhance the catalytic efficiency of degradation. Research funded by national science foundations often drives breakthroughs in chemical synthesis and medicinal chemistry, leading to more effective PROTAC candidates. The ongoing refinement of PROTAC design is critical for expanding their therapeutic window and broad applicability across various diseases.
• Emergence of Molecular Glues and Other Degraders: Beyond PROTACs, the protein degeneration therapy market is witnessing a strong trend in the emergence and development of other degradation modalities, particularly molecular glues. Molecular glues are small molecules that induce the formation of a new protein-protein interaction between an E3 ligase and a target protein, leading to the target's degradation. This mechanism can sometimes offer advantages in terms of oral bioavailability and simpler chemical structures compared to PROTACs. Additionally, other novel degradation approaches, such as Lysosome-Targeting Chimeras (LYTACs) for extracellular protein degradation, are gaining traction. This diversification of degradation platforms, often highlighted in biotechnology journals, reflects the industry's commitment to exploring multiple avenues for targeted protein elimination, expanding the reach and versatility of the protein degradation therapeutic landscape.
• Leveraging Artificial Intelligence and Machine Learning in Drug Discovery: A transformative trend in the protein degeneration therapy market is the increasing adoption of artificial intelligence (AI) and machine learning (ML) in drug discovery and development. AI algorithms are being utilized to rapidly identify novel E3 ligase-target protein interactions, predict optimal PROTAC and molecular glue designs, and screen vast chemical libraries for potential degraders. This accelerates the hit-to-lead and lead optimization phases, significantly reducing the time and cost associated with drug discovery. For example, the U.S. Department of Health and Human Services (HHS) encourages AI integration for drug development. AI can also aid in analyzing complex biological data, predicting off-target effects, and optimizing clinical trial design, thereby streamlining the entire development pipeline and bringing promising new therapies to patients more efficiently.
• Expansion of E3 Ligase Targets and Beyond: A crucial trend driving the future of protein degeneration therapy is the ongoing expansion of the repertoire of E3 ubiquitin ligases being harnessed for therapeutic purposes. Initially, much of the research focused on a few well-characterized E3 ligases, such as Cereblon (CRBN) and Von Hippel-Lindau (VHL). However, scientists are now actively exploring and recruiting a wider range of E3 ligases, which could enable the degradation of a broader spectrum of target proteins and potentially offer tissue-specific degradation. Research funded by government agencies focusing on cellular biology often explores the diverse functions of E3 ligases. This diversification of E3 ligase recruitment strategies is critical for overcoming limitations in target specificity, reducing off-target effects, and unlocking the full therapeutic potential of protein degradation across a wider array of diseases.

Contact Us

Segmentation Insights

Protein Degeneration Therapy Market Analysis, By Type

By Type, the market is categorized into Bavdegalutamide (ARV-110), Vepdegestrant (ARV-471), and Other Types.

• The largest segment in the Protein Degeneration Therapy market by type is Bavdegalutamide (ARV-110). This dominance is primarily attributed to its advanced clinical development status as one of the pioneering PROTAC molecules to enter human clinical trials. Bavdegalutamide specifically targets the androgen receptor (AR) for degradation, which is a key driver in metastatic castration-resistant prostate cancer. Its therapeutic potential in addressing a significant unmet need in oncology, particularly for patients who have developed resistance to existing anti-androgen therapies, has positioned it as a leading candidate in the protein degradation pipeline. The extensive preclinical data demonstrating its potent and selective degradation of AR, coupled with promising early clinical results, has solidified its leading position and attracted significant attention within the oncology therapeutic landscape.
• The fastest-growing segment in the Protein Degeneration Therapy market by type is Vepdegestrant (ARV-471). This rapid growth is driven by its strong potential as an oral PROTAC estrogen receptor (ER) degrader for ER-positive, HER2-negative advanced breast cancer. This type of breast cancer represents a large patient population, and Vepdegestrant offers a novel approach to overcoming resistance to current endocrine therapies. Its entry into late-stage clinical trials, including a global Phase III study, underscores its promising efficacy and safety profile observed in earlier phases. The high incidence of breast cancer globally, combined with the potential for Vepdegestrant to provide a new treatment option for a significant patient cohort, is accelerating its development and adoption, making it a rapidly expanding and highly anticipated therapeutic agent in the protein degradation space.

Protein Degeneration Therapy Market Analysis, By Application

By Application, the market is categorized into Oncology, Neurodegenerative Diseases, Infectious Diseases, and Other Applications.

• The largest segment in the Protein Degeneration Therapy market by application is Oncology. This dominance is due to the significant unmet medical need in cancer treatment, the vast number of disease-driving proteins in oncology, and the ability of protein degradation therapies to address drug resistance mechanisms. Many cancers are driven by specific proteins that are difficult to inhibit with traditional small molecules. Protein degraders offer a powerful way to selectively eliminate these proteins, even those considered "undruggable." The robust pipeline of protein degradation therapies in oncology clinical trials, aiming to treat various solid tumors and hematological malignancies, further solidifies this segment's leading position, attracting the majority of research and development investments in this field.
• The fastest-growing segment in the Protein Degeneration Therapy market by application is Neurodegenerative Diseases. This accelerated growth is primarily driven by the critical need for effective treatments for conditions like Alzheimer's, Parkinson's, and Huntington's disease, which are often characterized by the accumulation of toxic proteins. Protein degradation therapies offer a promising mechanism to directly remove these pathological protein aggregates, a fundamentally different approach from traditional therapies that often only target symptoms. Extensive research into the role of protein misfolding and aggregation in neurodegeneration is fueling the development of targeted degraders. The immense global burden of these diseases and the lack of disease-modifying treatments are propelling significant investment and rapid advancements in this therapeutic area.

Protein Degeneration Therapy Market Analysis, By End User

By End User, the market is categorized into Pharmaceutical Companies, Biotechnology Companies, and Academic and Research Institutes.

• The largest segment in the Protein Degeneration Therapy market by end user is Pharmaceutical Companies. This dominance is attributed to their extensive financial resources, robust drug development infrastructure, and established global commercialization capabilities. Large pharmaceutical companies are actively acquiring or licensing protein degradation technologies from smaller biotechnology firms and academic institutions, integrating these innovative platforms into their vast oncology and neurology pipelines. Their ability to fund and manage complex, multi-year clinical trials, navigate intricate regulatory pathways, and ultimately market approved therapies on a large scale positions them as the primary drivers of commercialization in this nascent but rapidly expanding therapeutic area, leading to significant investments in this promising modality.
• The fastest-growing segment in the Protein Degeneration Therapy market by end user is Biotechnology Companies. This rapid growth is driven by their agility, specialized expertise, and focus on cutting-edge scientific innovation in the targeted protein degradation space. Many pioneering discoveries and early-stage drug candidates in this field originate from biotechnology startups and specialized firms that are solely dedicated to developing protein degradation platforms. These companies often form strategic collaborations with larger pharmaceutical partners for late-stage clinical development and commercialization, leveraging their foundational scientific breakthroughs. The substantial venture capital funding flowing into the biotechnology sector for novel therapeutic modalities further fuels their rapid expansion and increasing contribution to the protein degradation therapy pipeline, positioning them as key innovators in the market.

Protein Degeneration Therapy Market Regional Insights

The market has been geographically analysed across five regions, Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

• The largest region in the Protein Degeneration Therapy market is North America. This dominance is primarily attributed to its robust biotechnology and pharmaceutical ecosystem, significant research and development investments, and a favorable regulatory environment. The United States, in particular, is a global hub for innovative drug discovery, with a high concentration of leading pharmaceutical companies, biotechnology firms, and academic research institutions actively engaged in protein degradation research and clinical trials. Substantial government funding for biomedical research from agencies like the National Institutes of Health (NIH), coupled with a strong venture capital landscape, accelerates the development and commercialization of these advanced therapies, solidifying North America's leading position in the global market.
• The fastest-growing region in the Protein Degeneration Therapy market is Asia-Pacific. This accelerated growth is driven by increasing healthcare investments, a rising prevalence of chronic diseases, and expanding biotechnology sectors in countries like China, Japan, and South Korea. There is a growing focus on pharmaceutical research and development within these nations, often supported by government initiatives promoting innovation in biopharmaceuticals and precision medicine. The large patient pool, particularly for oncology and neurodegenerative diseases, creates a significant unmet medical need that propels the adoption and development of novel therapies. Furthermore, lower operational costs for research and clinical trials in some parts of the region make it an attractive destination for drug development, fueling rapid market expansion.

Protein Degeneration Therapy Market Competitive Overview

The protein degeneration therapy market is characterized by intense competition among a relatively small but rapidly expanding group of biotechnology and pharmaceutical companies. The competitive landscape is primarily driven by intellectual property related to novel protein degrader platforms, the clinical advancement of pipeline candidates, and strategic partnerships. Companies are vying to identify new disease targets, optimize degrader design for improved potency and selectivity, and address challenges related to oral bioavailability and drug delivery. The focus is on building robust and diverse pipelines across various therapeutic areas, particularly oncology and neurodegenerative diseases. Strategic collaborations and licensing agreements are prevalent as firms seek to leverage complementary expertise and share the substantial costs associated with pioneering this innovative therapeutic modality.

Leading Market Players in the Protein Degeneration Therapy Market

• Arvinas Holding Company LLC: Arvinas Holding Company LLC is a pioneering biotechnology firm at the forefront of protein degradation therapy, specifically focusing on Proteolysis-Targeting Chimeras (PROTACs). The company has established a robust discovery engine designed to harness the body's natural protein disposal system to selectively degrade disease-causing proteins. Arvinas has advanced multiple investigational PROTACs into clinical development, primarily targeting oncology, with programs addressing significant unmet needs in prostate and breast cancers. Their strategic approach emphasizes rigorous preclinical validation, efficient clinical trial execution, and strategic collaborations to accelerate the development and potential commercialization of their innovative therapeutic candidates, aiming to transform the treatment landscape for patients with intractable diseases.
• Relay Therapeutics, Inc.: Relay Therapeutics, Inc. is an innovative biotechnology company that, while having a broader focus on protein motion for drug discovery, is actively engaged in the targeted protein degradation space. The company leverages its proprietary Dynamo platform, which integrates computational and experimental approaches to understand protein conformational dynamics. This unique insight allows Relay Therapeutics to design novel small molecules, including those that can act as protein degraders, to tackle challenging disease targets. Their strategic focus is on developing precision medicines, particularly in oncology and rare diseases, by unlocking the therapeutic potential of previously "undruggable" proteins through a deep understanding of their dynamic behavior.
• Kymera Therapeutics, Inc.: Kymera Therapeutics, Inc. is a leading biotechnology company dedicated to discovering and developing novel small molecule protein degradation therapies. The company has built a comprehensive targeted protein degradation platform that allows for the precise and selective elimination of disease-causing proteins. Kymera's pipeline spans various therapeutic areas, including immunology and oncology, with lead programs addressing conditions like hidradenitis suppurativa and specific cancers. Their strategic emphasis is on leveraging their deep expertise in ubiquitin biology and medicinal chemistry to create best-in-class degraders. The company actively pursues research and development to expand its platform, identify new E3 ligase targets, and bring transformative medicines to patients.

Top Strategies Followed by Players

• Strategic Collaborations and Licensing Agreements: A pervasive strategy adopted by key players in the protein degradation therapy market is forming strategic collaborations and entering into licensing agreements. Given the complexity and high cost of drug development in this novel field, partnerships enable companies to pool resources, share expertise, and mitigate financial risks. For instance, major pharmaceutical companies often partner with biotechnology firms that possess proprietary protein degradation platforms or advanced preclinical candidates. Data from industry analyses indicate a significant increase in such partnerships, with numerous multi-billion dollar deals announced. These collaborations, often involving upfront payments, milestone remunerations, and tiered royalties, are crucial for accelerating the discovery, development, and eventual commercialization of protein degradation therapies, fostering a synergistic environment for innovation.
• Robust Investment in Research and Development: Leading companies in the protein degradation therapy market are characterized by their substantial and sustained investments in research and development (R&D). This commitment is essential for pioneering new degradation modalities, identifying novel disease targets, and optimizing the design of PROTACs and molecular glues for enhanced potency, selectivity, and pharmacokinetic properties. R&D efforts also focus on overcoming technical challenges such as off-target effects and oral bioavailability. The U.S. National Institutes of Health (NIH) consistently funds cutting-edge research in chemical biology and drug discovery, contributing to the foundational knowledge that drives these investments. This strong R&D focus is critical for maintaining a competitive edge, building a robust pipeline of therapeutic candidates, and ultimately bringing transformative medicines to patients.
• Pipeline Expansion and Diversification Across Therapeutic Areas: A key strategy for market players is to continuously expand and diversify their therapeutic pipelines across various disease areas, moving beyond the initial focus on oncology. While cancer remains a dominant application, companies are increasingly exploring the potential of protein degradation therapies for neurodegenerative diseases, autoimmune disorders, and infectious diseases. This diversification strategy aims to broaden the addressable market and reduce reliance on a single therapeutic area. By targeting a wider range of disease-causing proteins implicated in different pathologies, companies can leverage their core protein degradation platforms across multiple indications. Industry reports show a growing number of preclinical and clinical programs targeting diverse therapeutic areas, reflecting this strategic shift towards a more comprehensive approach to drug development.

 List of Companies Profiled in the Report are:

• Arvinas Holding Company LLC
• Relay Therapeutics Inc.
• Kymera Therapeutics Inc.
• Nurix Therapeutics Inc.
• Vividion Therapeutics Inc.
• Mission Therapeutics Ltd.
• C4 Therapeutics Inc.
• Frontier Medicines Inc.
• Foghorn Therapeutics Inc.
• Aileron Therapeutics Inc.
• Ribometrix Inc.
• Nimbus Therapeutics Inc.
• Jnana Therapeutics Inc.
• KSQ Therapeutics Inc.
• Stoke Therapeutics Inc.

Global Protein Degeneration Therapy Market Report Scope and Key Segmentation

List of Segments Covered

This section of the Protein Degeneration Therapy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

 By Type

• Bavdegalutamide (ARV-110)
• Vepdegestrant (ARV-471)
• Other Types

By Application

• Oncology
• Neurodegenerative Diseases
• Infectious Diseases
• Other Applications

 By End User

• Pharmaceutical Companies
• Biotechnology Companies
• Academic and Research Institutes